Ritu Baral Recent News
Cowen Lifts Intercept's Price Target To $215 Following Ocaliva Approval
Cowen Suspends PTC Therapeutics Target, Puts Rating Under Review
Did The AAN Meeting Affect Biogen, PTC Therapeutics, GW Pharma Or Isis Pharma?
Cowen Says PTC Therapeutics Is A Buy
Cowen And Company Analyst Explains Why Intercept Pharmaceuticals Is 'Absolutely A Buy'
Cowen Analyst Likes Intercept Pharmaceuticals, ACADIA Pharmaceuticals And Raptor Pharmaceutical
UPDATE: Canaccord Genuity Downgrades Sarepta Therapeutics as FDA Talks Continue
UPDATE: Canaccord Reiterates On Synergy Pharmaceuticals On Unmet Potential Of Plecanatide
UPDATE: Canaccord Genuity Initiates Coverage on Mast Therapeutics on MST-188 Potential
UPDATE: Canaccord Genuity Initiates Coverage on Regado Biosciences on Strong REG1 Potential
Avanir Shares Rebound As Analysts Offer Defense On Heels of 13% Drop
UPDATE: Canaccord Genuity Downgrades Vical Following Allovectin Failure
UPDATE: Canaccord Genuity Downgrades Optimer Pharmaceuticals Following Merger Proposal
Canaccord Genuity Reiterates Buy on Cytokinetics on CK357 Potential